Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details)

Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests	$ (30,549)	$ (25,080)	$ (96,841)	$ (63,180)	$ (100,123)
Non-controlling interests in consolidated entities	39,681		39,681		117,203
Urica
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			(870)		(1,353)
Non-controlling interests in consolidated entities	$ (1,182)		$ (1,182)		$ (1,795)
Non-controlling ownership	34.50%		34.50%		34.50%
Aevitas [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (475)		$ (901)
Non-controlling interests in consolidated entities	$ (5,637)		$ (5,637)		$ (5,060)
Non-controlling ownership	45.20%		45.20%		45.90%
Avenue [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (2,984)		$ (2,909)
Non-controlling interests in consolidated entities	$ (31)		$ (31)		$ 2,830
Non-controlling ownership	81.80%		81.80%		82.00%
Baergic [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (261)		$ (39)
Non-controlling interests in consolidated entities	$ (2,434)		$ (2,434)		$ (2,086)
Non-controlling ownership	39.00%		39.00%		39.00%
Cellvation [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (161)		$ (131)
Non-controlling interests in consolidated entities	$ (1,759)		$ (1,759)		$ (1,544)
Non-controlling ownership	21.70%		21.70%		21.70%
Checkpoint [Member].
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (33,568)		$ (39,226)
Non-controlling interests in consolidated entities	$ (1,078)		$ (1,078)		$ 24,238
Non-controlling ownership	80.70%		80.70%		81.50%
Coronado SO [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ 0		$ 0
Non-controlling interests in consolidated entities	$ (290)		$ (290)		$ (290)
Non-controlling ownership	13.00%		13.00%		13.00%
Cyprium [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (732)		$ (807)
Non-controlling interests in consolidated entities	$ (3,272)		$ (3,272)		$ (2,204)
Non-controlling ownership	29.00%		29.00%		29.80%
Helocyte [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (283)		$ (89)
Non-controlling interests in consolidated entities	$ (5,787)		$ (5,787)		$ (5,529)
Non-controlling ownership	17.90%		17.90%		18.30%
JMC [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (7,355)		$ (5,652)
Non-controlling interests in consolidated entities	$ 11,189		$ 11,189		$ 17,498
Non-controlling ownership	42.70%		42.70%		41.60%
Mustang [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (49,944)		$ (48,518)
Non-controlling interests in consolidated entities	$ 52,225		$ 52,225		$ 93,009
Non-controlling ownership	81.20%		81.20%		82.70%
Oncogenuity [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (187)		$ (497)
Non-controlling interests in consolidated entities	$ (1,495)		$ (1,495)		$ (1,124)
Non-controlling ownership	27.40%		27.40%		24.90%
Tamid [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (21)		$ (1)
Non-controlling interests in consolidated entities	$ (768)		$ (768)		$ (740)
Non-controlling ownership	22.80%		22.80%		22.80%